Search Results

Forward Pharma A/S announced that its Board of Directors has approved a termination of the Deposit Agreement, dated October 14, 2014, among Forward Pharma A/S, the Depositary Bank of New York Mellon, and Owners and Holders of ADRs.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from 14 ordinary shares per ADS to 4000 ordinary shares per ADS.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.

Today, new data from the Phase 1/2 FORWARD clinical study of the VX-880 islet cell therapy was presented at a symposium at the American Diabetes Association® (ADA) 84th Scientific Sessions in Orlando, FL.

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.

ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.